1.	Peripheral Blood Lymphocyte Therapy to Prevent Lymphoproliferative Disorders Caused by Epstein-Barr Virus in Patients Who Have Undergone Transplantation Phase: Phase II Type: Treatment Status: Completed Age: Not specified Sponsor: NCI, Other Protocol IDs: NU 98H1, NCI-G00-1739, NCT00005606
2.	Phase I Pilot Study to Evaluate the Toxic Effects of Allogeneic Epstein-Barr Virus (EBV) Specific Cytotoxic T Lymphocytes for EBV Associated Lymphoproliferative Diseases in Organ Transplant Recipients (Summary Last Modified 08/2000) Phase: Phase I Type: Treatment Status: Completed Age: Not specified Sponsor: Other Protocol IDs: UAB-9739, IUMC-9611-37, NCI-V97-1176, NCT00002956
3.	Phase I Pilot Study of Allogeneic Epstein Barr Virus (EBV)-Specific Cytotoxic T-Lymphocytes in Patients With Progressive, Relapsed, or Refractory EBV-Positive Hodgkin's Lymphoma Phase: Phase I Type: Treatment Status: Closed Age: 18 to 75 Sponsor: NCI Protocol IDs: PSCI-2003-257, UAB-0002, NCI-G00-1829, NCT00006100